These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8355505)

  • 1. A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes.
    Harada M; Shibuya T; Teshima T; Murakawa M; Okamura T; Niho Y; Gondo H; Hayashi S; Akashi K; Tamura K
    Leuk Res; 1993 Aug; 17(8):629-32. PubMed ID: 8355505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of four patients with myelodysplastic syndrome with a small dose of aclacinomycin-A.
    Shibuya T; Morioka E; Taniguchi S; Ohhara N; Okamura S; Niho Y
    Leuk Res; 1987; 11(10):851-4. PubMed ID: 3479662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicin.
    Shibuya T; Teshima T; Harada M; Taniguchi S; Okamura T; Okamura S; Niho Y
    Leuk Res; 1990; 14(2):161-7. PubMed ID: 2179636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
    Ohno R; Kimura K
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1205-8. PubMed ID: 3382195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary myelodysplastic syndrome: an analysis of 56 patients.
    Chen PH; Kuo CY; Huang CH; Shih LY
    Changgeng Yi Xue Za Zhi; 1992 Sep; 15(3):121-7. PubMed ID: 1468034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
    Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
    Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
    Katayama N; Tanaka I; Minami N; Shirakawa S
    Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
    Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
    Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
    Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
    Nair R; Saikia TK; Gopal R; Nair CN; Soman CS; Advani SH
    J Assoc Physicians India; 1996 Mar; 44(3):181-3. PubMed ID: 9251314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study on pathophysiology of the myelodysplastic syndromes (MDS)--pattern of dysmegakaryopoiesis related to leukemic transformation].
    Tomonaga M; Jinnai I; Kuriyama K; Nonaka H; Amenomori T; Matsuo T; Yoshida Y; Sasagawa I; Sadamori N; Ichimaru M
    Rinsho Ketsueki; 1989 Oct; 30(10):1788-99. PubMed ID: 2593245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
    Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
    Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
    Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
    Zwierzina H; Suciu S; Loeffler-Ragg J; Neuwirtova R; Fenaux P; Beksac M; Harousseau J; Nuessler V; Cermak J; Solbu G; Willemze R; de Witte T; Amadori S;
    Leukemia; 2005 Nov; 19(11):1929-33. PubMed ID: 16151466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
    Xu WL; Jin J; Qian WB
    Chin Med J (Engl); 2010 Jan; 123(1):108-10. PubMed ID: 20137586
    [No Abstract]   [Full Text] [Related]  

  • 20. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
    Guan M; Chen SC; Ge CW
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.